PAB 10.0% 0.9¢ patrys limited

PAB chart, page-1663

  1. 4,680 Posts.
    lightbulb Created with Sketch. 1083
    Mmm don't know about that Stock.

    A liquidity event before human trials will certainly be more than 10c.....overwise PAB goes alone into clinical trials....no point selling to Pharma for under 10c at $190m valuation.

    The opportunity for Pharma is unique here with PAB - the patents behind the unique MOA are gold....it's not like any other antibody tech.

    Peer comparison against NASDAQ antibody companies is my guidepost for valuation.

    The Yale connection, US based board directors and North American sub holders in top 10 tells me the valuations will be measured per NASDAQ metrics.

    The lowest pre-clinical antibody deal size in the last 3 years was around AU$350m - off the top of my head. Most deals were between $1B and $6B.

    Let's see what Pharma thinks when tox studies are complete and we're ready for the clinic.

    I'm tipping +20c valuation min before clinic.
    .
 
watchlist Created with Sketch. Add PAB (ASX) to my watchlist
(20min delay)
Last
0.9¢
Change
-0.001(10.0%)
Mkt cap ! $18.51M
Open High Low Value Volume
1.0¢ 1.0¢ 0.9¢ $6.454K 658.9K

Buyers (Bids)

No. Vol. Price($)
18 6367122 0.9¢
 

Sellers (Offers)

Price($) Vol. No.
1.0¢ 2855358 5
View Market Depth
Last trade - 14.14pm 28/03/2024 (20 minute delay) ?
Last
0.9¢
  Change
-0.001 ( 10.0 %)
Open High Low Volume
1.0¢ 1.0¢ 0.9¢ 2467579
Last updated 14.14pm 28/03/2024 ?
PAB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.